SenoRx, Inc. (NASDAQ:SENO)

CAPS Rating: No stars

The Company develops, manufactures and sells minimally-invasive medical devices for the diagnosis of breast cancer.

Results 1 - 3 of 3

Recs

0
Member Avatar MstrGold (31.64) Submitted: 6/9/2010 6:49:39 AM : Underperform Start Price: $7.03 SENO Score: +12.98

Company is overvalued in terms of fundamental prospects (source Ultralong).

Recs

0
Member Avatar jhe2jhe (33.50) Submitted: 9/27/2007 7:01:37 PM : Outperform Start Price: $8.38 SENO Score: -4.35

Great startup will do well. Very good business lan in a much needed area with outstanding products

Recs

0
Member Avatar JhansiKiRani (67.01) Submitted: 6/27/2007 11:44:42 AM : Outperform Start Price: $9.83 SENO Score: -27.92

It's already outeperformed S & P once.

Results 1 - 3 of 3

Featured Broker Partners


Advertisement